200 related articles for article (PubMed ID: 35344524)
1. Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.
Gatti M; Campoli C; Belotti T; Cojutti PG; Masetti R; Pession A; Viale P; Pea F
Ther Drug Monit; 2022 Oct; 44(5):641-650. PubMed ID: 35344524
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
8. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting.
Ping Y; Hongmei J; Bellmann C; Inês M; Macmillan T; Webb N; Aram JA; Penack O
Hematology; 2022 Dec; 27(1):723-732. PubMed ID: 35688453
[TBL] [Abstract][Full Text] [Related]
10. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
11. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
13. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Mycoses; 2023 Sep; 66(9):815-824. PubMed ID: 37300337
[TBL] [Abstract][Full Text] [Related]
16. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
17. A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings.
Gatti M; Cojutti PG; Campoli C; Caramelli F; Corvaglia LT; Lanari M; Pession A; Ramirez S; Viale P; Pea F
Front Pharmacol; 2021; 12():755075. PubMed ID: 34646143
[No Abstract] [Full Text] [Related]
18. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
[TBL] [Abstract][Full Text] [Related]
19. Interaction between flucloxacillin and azoles: Is isavuconazole next?
Van Daele R; Wauters J; Vandenbriele C; Lagrou K; Vos R; Debaveye Y; Spriet I
Mycoses; 2021 Dec; 64(12):1508-1511. PubMed ID: 34553797
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
